402:
Age-Related
Macular Degeneration Treatment Trials (CATT Study), enrolled about 1,200 patients with newly diagnosed wet AMD. The patients were assigned randomly to different treatment groups, and the data was collected from 2008 to 2009. So far, the result has been at least 41 papers and 10 editorials/commentaries published in major medical journals. An additional paper is in press and work proceeds on 10 more. The overall conclusions demonstrated no statistical difference between the treatment groups outcomes after eight years
405:
By May 2012, anti-VEGF treatment with
Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011)
401:
In
October 2006, the National Eye Institute (NEI) of the National Institutes of Health (NIH) announced that it would fund a comparative study trial of ranibizumab and bevacizumab to assess the relative efficacy and ocular adversity in treating wet AMD. In 2008, this study, called the Comparison of
390:
In 2007, Raftery, et al. reported in the
British Journal of Ophthalmology that, unless ranibizumab is 2.5 times more effective the bevacizumab, ranibizumab is not cost-effective. It was concluded that the price of ranibizumab would have to be drastically reduced for the drug to be cost-effective.
366:
In the
October 2006 issue of the New England Journal of Medicine (NEJM), Rosenfield, et al. reported that monthly intravitreal injection of ranibizumab led to significant increase in the level of mean visual acuity compared to that of sham injection. It was concluded from the two-year, phase III
397:
of intravitreal bevacizumab has become a widespread treatment for neovascular age-related macular degeneration. Although the drug is not FDA-approved for non-oncologic uses, some studies suggest that bevacizumab is effective in increasing visual acuity with low rates of ocular adverse effects.
386:
Although the efficacy of ranibizumab is well-supported by extensive clinical trials, the cost effectiveness of the drug is questioned. Since the drug merely stabilizes patient conditions, ranibizumab must be administered monthly. At a cost of $ 2,000.00 per injection, the cost to treat wet AMD
374:
Another study published in the
January 2009 issue of Ophthalmology provides the evidence for the efficacy of ranibizumab. Brown, et al. reported that monthly intravitreal injection of ranibizumab led to significant increase in the level of mean visual acuity compared to that of
150:
Bergers and
Hanahan concluded in 2008 that anti-VEGF drugs can show therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. But, "the benefits are at best transitory and are followed by a restoration of tumour growth and progression."
617:
Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MK (March 2016).
453:
Anti-VEGF subconjunctival injections have been proposed as a means of controlling wound healing during glaucoma surgery, however the evidence for or against this therapeutic approach is limited and several studies are ongoing.
383:. It was concluded from the two year, phase III study that ranibizumab was superior to photodynamic therapy with verteporfin in the treatment of predominantly classic (PC) Wet AMD with low rates of ocular adverse effects.
786:
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (January 2009). "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study".
154:
Later studies into the consequences of VEGF inhibitor use have shown that, although they can reduce the growth of primary tumours, VEGF inhibitors can concomitantly promote invasiveness and metastasis of tumours.
445:
in patients with neovascular glaucoma was inconclusive, as more research is needed to compare anti-VEGF treatments with conventional treatments. A 2017 review update found moderate evidence that in patients with
387:
patients in the United States is greater than $ 10.00 billion per year. Due to high cost, many ophthalmologists have turned to bevacizumab as the alternative intravitreal agent in the treatment of wet AMD.
1164:
340:
The most common indication for anti-VEGF therapy is cancer, and they are FDA and EMA approved for many forms of cancer. These medications are one of the most used forms of
3079:
1157:
4039:
3695:
2843:
162:), a multi-targeted tyrosine kinase inhibitor has been shown to have anti-edema effects by reducing the permeability and aiding in vascular normalization.
2460:
1150:
2518:
3380:
3070:
2675:
177:. Participants in both treatment groups showed improvement in visual acuity measures and a reduction in macular edema symptoms over six months.
1660:
1343:
4058:
4008:
3979:
3926:
2413:
2280:
620:"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial"
3737:
3733:
3729:
3725:
1278:
1262:
2006:
1925:
1792:
1709:
3721:
97:
3410:
2529:
2089:
1700:
431:
1358:
1302:
1293:
360:
101:
3932:
945:"Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro"
4019:
3995:
3135:
2691:
2554:
174:
3985:
992:
Simha, Arathi; Aziz, Kanza; Braganza, Andrew; Abraham, Lekha; Samuel, Prasanna; Lindsley, Kristina B. (6 February 2020).
568:
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O (March 2009).
4029:
2425:
2307:
2297:
359:, has been developed by Genentech for intraocular use. In 2006, FDA approved the drug for the treatment of neovascular
3375:
3400:
4101:
4014:
1840:
570:"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis"
367:
study that ranibizumab is very effective in the treatment of minimally classic (MC) or occult wet AMD (age-related
3395:
139:
Both antibody-based compounds and the first three orally available compounds are commercialized. The latter two,
3922:
450:, aflibercept may have advantages in improving visual outcomes over bevacizumab and ranibizumab, after one year.
760:
2106:
2022:
1941:
1808:
1725:
1540:
1098:
Cheng, Jin-Wei; Cheng, Shi-Wei; Wei, Rui-Li; Lu, Guo-Cai (2016-01-15). Cochrane Eyes and Vision Group (ed.).
3706:
1453:
1328:
438:
3385:
441:
seeking to determine the effectiveness of anti-VEGF agents such as ranibizumab and bevacizumab on lowering
3990:
3606:
3510:
3370:
3130:
2549:
1535:
1173:
166:
919:
4064:
2261:
1905:
1545:
1184:
664:"Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion"
398:
However, due to small sample size and lack of randomized control trial, the result is not conclusive.
4004:
3390:
2322:
2271:
447:
442:
376:
368:
3140:
1215:
3145:
2559:
2256:
1448:
2181:
920:
Patent Docs: Genentech Acts to Halt Off-label Use of
Avastin® for Age-related Macular Degeneration
4096:
3763:
3676:
3621:
3575:
3520:
3255:
3195:
2823:
2196:
2126:
1685:
1283:
1225:
1176:
853:
521:"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis"
419:
3758:
3636:
3535:
3321:
3210:
3010:
2970:
2718:
2637:
2499:
2440:
2402:
2347:
2342:
2332:
2206:
2201:
2171:
2146:
2141:
2131:
2017:
1936:
1875:
1803:
1782:
1767:
1720:
1373:
3858:
3716:
3651:
3631:
3550:
3530:
3245:
3225:
3205:
2848:
2176:
1900:
1433:
1230:
3681:
3671:
3626:
3580:
3570:
3525:
3450:
3349:
3316:
3296:
3260:
3250:
3200:
3160:
2632:
2612:
2579:
2362:
2211:
1129:
1080:
1051:"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis"
1031:
1013:
974:
902:
845:
804:
742:
693:
641:
599:
550:
501:
423:
38:
3641:
3540:
3435:
3339:
3291:
3284:
3270:
3215:
3185:
2665:
2655:
2607:
2589:
2352:
2191:
2136:
410:(Eylea). Tests on these treatments are ongoing relative to the efficacy of one over another.
3868:
3000:
1119:
1111:
1070:
1062:
1021:
1005:
964:
956:
892:
884:
835:
796:
732:
724:
683:
675:
631:
589:
581:
540:
532:
491:
483:
341:
70:
2392:
3480:
1100:"Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery"
113:
822:
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (October 2006).
4054:
3975:
3917:
3611:
3460:
3455:
2569:
2564:
1210:
1200:
1195:
1124:
1099:
1075:
1050:
1026:
993:
969:
944:
897:
872:
737:
712:
688:
663:
594:
569:
545:
520:
496:
471:
427:
636:
619:
4090:
3748:
3661:
3590:
3560:
3495:
3405:
3359:
3235:
3165:
3110:
3099:
2584:
2292:
1975:
1880:
1772:
960:
519:
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (March 2009).
394:
133:
1142:
857:
4074:
4044:
3783:
3773:
3666:
3565:
3420:
3240:
3175:
3090:
2594:
2397:
2236:
2231:
2151:
2101:
1915:
1669:
1650:
1629:
1600:
1323:
1318:
1115:
1066:
1009:
873:"Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness"
679:
229:
219:
943:
Shah DK, Menon KM, Cabrera LM, Vahratian A, Kavoussi SK, Lebovic DI (April 2010).
800:
4034:
4000:
3898:
3888:
3883:
3873:
3823:
3646:
3545:
3306:
3220:
3150:
3045:
2808:
2773:
2723:
2686:
2622:
2504:
2435:
2387:
2377:
2372:
2367:
2251:
2246:
2241:
1619:
1530:
1520:
1488:
1483:
1478:
1473:
1463:
1423:
1388:
728:
407:
380:
356:
352:
299:
289:
279:
209:
109:
105:
17:
3853:
3818:
3813:
3803:
3793:
3711:
3500:
3475:
3465:
3311:
3265:
3125:
2951:
2920:
2889:
2858:
2803:
2778:
2758:
2743:
2733:
2627:
2544:
2337:
2317:
2216:
2161:
2156:
1980:
1885:
1870:
1665:
1624:
1596:
1565:
1525:
1428:
1383:
1378:
1353:
1348:
1338:
1251:
1245:
1235:
761:"FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration"
585:
536:
329:
249:
170:
1017:
3878:
3848:
3843:
3838:
3833:
3828:
3808:
3798:
3788:
3778:
3470:
3430:
3326:
3301:
3060:
3055:
3050:
3040:
3035:
3030:
3020:
2941:
2879:
2813:
2793:
2788:
2783:
2768:
2763:
2753:
2748:
2642:
2617:
2382:
2302:
2221:
2166:
2056:
1995:
1985:
1890:
1777:
1575:
1570:
1560:
1468:
1458:
1443:
1418:
1413:
1403:
1398:
1393:
888:
363:(wet AMD). The drug had undergone three successful clinical trials by then.
319:
309:
269:
259:
239:
159:
144:
129:
121:
117:
1133:
1084:
1049:
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E (October 2018).
1035:
978:
930:
906:
849:
808:
746:
697:
645:
603:
554:
505:
50:
4049:
3768:
3425:
3025:
3015:
2995:
2930:
2899:
2868:
2832:
2738:
2728:
2075:
1555:
1498:
1408:
1368:
840:
823:
199:
140:
125:
4024:
3445:
2910:
2312:
1273:
3937:
3601:
3490:
3415:
3120:
3115:
2539:
2534:
2488:
2484:
2480:
2476:
2472:
2468:
2464:
2116:
1655:
1333:
487:
3969:
3965:
3961:
3957:
3953:
3949:
3945:
3941:
3656:
3555:
3230:
3170:
2984:
2707:
2703:
2699:
2695:
2186:
2050:
1969:
1965:
1864:
1860:
1856:
1852:
1761:
1757:
1608:
994:"Anti-vascular endothelial growth factor for neovascular glaucoma"
112:(Lucentis), or orally-available small molecules that inhibit the
3440:
2046:
2042:
2038:
2034:
2030:
2026:
1961:
1957:
1953:
1949:
1945:
1848:
1844:
1836:
1832:
1828:
1824:
1820:
1816:
1812:
1753:
1749:
1745:
1741:
1737:
1733:
1729:
1681:
1677:
1673:
1639:
1604:
1585:
871:
Raftery J, Clegg A, Jones J, Tan SC, Lotery A (September 2007).
1146:
824:"Ranibizumab for neovascular age-related macular degeneration"
662:
Braithwaite T, Nanji AA, Lindsley K, Greenberg PB (May 2014).
344:
and are typically used in combination with other medications.
96:) therapy or medication, is the use of medications that block
85:
76:
100:. This is done in the treatment of certain cancers and in
79:
430:
gives the potential of thiazolidinediones to be used in
4040:
Pituitary adenylate cyclase-activating peptide (PACAP)
88:
355:, a monoclonal antibody fragment (Fab) derived from
73:
3907:
3694:
3589:
3358:
3098:
3089:
3069:
2983:
2960:
2929:
2898:
2867:
2831:
2822:
2674:
2517:
2450:
2412:
2279:
2270:
2088:
2065:
2005:
1924:
1791:
1708:
1699:
1638:
1584:
1497:
1301:
1292:
1261:
1183:
82:
37:
32:
3986:Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
2844:Glial cell line-derived neurotrophic factor (GDNF)
2497:Cleavage products/derivatives with unknown target:
657:
655:
104:. They can involve monoclonal antibodies such as
4020:Macrophage-stimulating protein (MSP; HLP, HGFLP)
472:"Modes of resistance to anti-angiogenic therapy"
426:type 2 and related disease), and this effect on
1661:Heparin-binding EGF-like growth factor (HB-EGF)
1344:Heparin-binding EGF-like growth factor (HB-EGF)
173:, on patients who have macular edema caused by
61:Anti–vascular endothelial growth factor therapy
27:Medication which blocks growth of blood vessels
4072:Additional growth factor receptor modulators:
1158:
169:studied the effectiveness of ranibizumab and
8:
2426:Insulin-like growth factor-2 (somatomedin A)
2308:Insulin-like growth factor-2 (somatomedin A)
2298:Insulin-like growth factor-1 (somatomedin C)
371:) with low rates of ocular adverse effects.
348:Neovascular age-related macular degeneration
1055:The Cochrane Database of Systematic Reviews
998:The Cochrane Database of Systematic Reviews
717:Cold Spring Harbor Perspectives in Medicine
668:The Cochrane Database of Systematic Reviews
3095:
2828:
2276:
1705:
1298:
1165:
1151:
1143:
184:
1123:
1074:
1025:
968:
896:
839:
736:
687:
635:
593:
544:
495:
4030:Migration-stimulating factor (MSF; PRG4)
931:https://www.med.upenn.edu/cpob/catt.html
1359:Transforming growth factor alpha (TGFα)
1104:Cochrane Database of Systematic Reviews
711:Meadows KL, Hurwitz HI (October 2012).
462:
3933:Connective tissue growth factor (CTGF)
29:
3996:Hepatoma-derived growth factor (HDGF)
7:
877:The British Journal of Ophthalmology
470:Bergers G, Hanahan D (August 2008).
828:The New England Journal of Medicine
713:"Anti-VEGF therapies in the clinic"
46:
98:vascular endothelial growth factor
25:
432:ovarian hyperstimulation syndrome
4015:Leukemia inhibitory factor (LIF)
961:10.1016/j.fertnstert.2009.02.059
361:age-related macular degeneration
132:(some of these therapies target
102:age-related macular degeneration
69:
3183:Negative allosteric modulators:
108:, antibody derivatives such as
3501:Gossypetin (3,5,7,8,3',4'-HHF)
2692:Platelet-derived growth factor
1116:10.1002/14651858.CD009782.pub2
1067:10.1002/14651858.CD007419.pub6
1010:10.1002/14651858.CD007920.pub3
680:10.1002/14651858.CD007325.pub3
175:central retinal vein occlusion
1:
3707:Placental growth factor (PGF)
637:10.1016/S0140-6736(15)01167-8
186:FDA-approved anti-VEGF drugs
3991:Glia maturation factor (GMF)
2500:Glypromate (GPE, (1-3)IGF-1)
801:10.1016/j.ophtha.2008.10.018
729:10.1101/cshperspect.a006577
4118:
3923:Colony-stimulating factors
3915:Additional growth factors:
418:VEGF is also inhibited by
167:Cochrane Systematic Review
147:, are in clinical trials.
3271:SNA-120 (pegylated K252a)
2443:(against IGF-1 and IGF-2)
2405:(against IGF-1 and IGF-2)
586:10.1016/j.ccr.2009.01.027
537:10.1016/j.ccr.2009.01.021
47:
2107:Hepatocyte growth factor
1666:Neuregulins (heregulins)
1597:Neuregulins (heregulins)
1541:Trastuzumab duocarmazine
1254:(against angiopoietin 2)
1248:(against angiopoietin 3)
136:rather than the VEGFs).
1454:Depatuxizumab mafodotin
949:Fertility and Sterility
889:10.1136/bjo.2007.116616
4077:(neurotrophin mixture)
4065:Wnt signaling proteins
3746:Allosteric modulators:
3466:Norwogonin (5,7,8-THF)
1686:5 (tomoregulin, TMEFF)
1536:Trastuzumab deruxtecan
1174:Growth factor receptor
476:Nature Reviews. Cancer
448:diabetic macular edema
4005:T-cell growth factors
2262:Telisotuzumab vedotin
1546:Trastuzumab emtansine
765:FDA News & Events
2590:EVT-901 (SAR-127963)
2323:Mecasermin rinfabate
841:10.1056/NEJMoa054481
630:(10023): 1066–1074.
443:intraocular pressure
377:photodynamic therapy
369:macular degeneration
116:stimulated by VEGF:
933:| Date=January 2022
187:
3756:Kinase inhibitors:
3619:Kinase inhibitors:
3518:Kinase inhibitors:
3193:Kinase inhibitors:
3008:Kinase inhibitors:
2968:Kinase inhibitors:
2949:Kinase inhibitors:
2918:Kinase inhibitors:
2887:Kinase inhibitors:
2856:Kinase inhibitors:
2716:Kinase inhibitors:
2330:Kinase inhibitors:
2124:Kinase inhibitors:
1913:Kinase inhibitors:
1906:Aprutumab ixadotin
1553:Kinase inhibitors:
1366:Kinase inhibitors:
1223:Kinase inhibitors:
420:thiazolidinediones
185:
4102:Cancer treatments
4084:
4083:
3690:
3689:
3451:N-Acetylserotonin
3350:ReN-1820 (TrkAd5)
2979:
2978:
2513:
2512:
2458:Binding proteins:
2117:Dihexa (PNB-0408)
2084:
2083:
1695:
1694:
1609:6 (neuroglycan C)
1329:EGF (urogastrone)
1307:
424:diabetes mellitus
338:
337:
58:
57:
16:(Redirected from
4109:
3896:Decoy receptors:
3869:Alacizumab pegol
3347:Decoy receptors:
3096:
3001:Stem cell factor
2942:Persephin (PSPN)
2880:Neurturin (NRTN)
2829:
2666:LEVI-04 (p75-Fc)
2663:Decoy receptors:
2277:
1706:
1305:
1299:
1167:
1160:
1153:
1144:
1138:
1137:
1127:
1095:
1089:
1088:
1078:
1061:(10): CD007419.
1046:
1040:
1039:
1029:
989:
983:
982:
972:
940:
934:
928:
922:
917:
911:
910:
900:
868:
862:
861:
843:
819:
813:
812:
783:
777:
776:
774:
772:
757:
751:
750:
740:
708:
702:
701:
691:
659:
650:
649:
639:
614:
608:
607:
597:
565:
559:
558:
548:
516:
510:
509:
499:
467:
342:targeted therapy
188:
114:tyrosine kinases
95:
94:
91:
90:
87:
84:
81:
78:
75:
63:, also known as
51:edit on Wikidata
30:
21:
18:Anti-VEGF agents
4117:
4116:
4112:
4111:
4110:
4108:
4107:
4106:
4087:
4086:
4085:
4080:
4025:Midkine (NEGF2)
3903:
3686:
3585:
3354:
3292:ABT-110 (PG110)
3085:
3065:
2975:
2956:
2925:
2894:
2863:
2818:
2670:
2608:ABT-110 (PG110)
2509:
2446:
2408:
2266:
2080:
2061:
2001:
1998:(against FGF23)
1920:
1787:
1691:
1634:
1580:
1493:
1304:
1288:
1257:
1179:
1171:
1141:
1110:(1): CD009782.
1097:
1096:
1092:
1048:
1047:
1043:
1004:(2): CD007920.
991:
990:
986:
942:
941:
937:
929:
925:
918:
914:
870:
869:
865:
834:(14): 1419–31.
821:
820:
816:
795:(1): 57–65.e5.
785:
784:
780:
770:
768:
767:. June 30, 2006
759:
758:
754:
723:(10): a006577.
710:
709:
705:
674:(5): CD007325.
661:
660:
653:
616:
615:
611:
567:
566:
562:
518:
517:
513:
488:10.1038/nrc2442
469:
468:
464:
460:
439:Cochrane Review
428:granulosa cells
416:
350:
183:
72:
68:
54:
28:
23:
22:
15:
12:
11:
5:
4115:
4113:
4105:
4104:
4099:
4089:
4088:
4082:
4081:
4079:
4078:
4068:
4067:
4062:
4055:Thrombopoietin
4052:
4047:
4042:
4037:
4032:
4027:
4022:
4017:
4012:
3998:
3993:
3988:
3983:
3976:Erythropoietin
3973:
3935:
3930:
3920:
3918:Adrenomedullin
3911:
3909:
3905:
3904:
3902:
3901:
3892:
3891:
3886:
3881:
3876:
3871:
3862:
3861:
3856:
3851:
3846:
3841:
3836:
3831:
3826:
3821:
3816:
3811:
3806:
3801:
3796:
3791:
3786:
3781:
3776:
3771:
3766:
3761:
3752:
3751:
3742:
3741:
3719:
3714:
3709:
3700:
3698:
3692:
3691:
3688:
3687:
3685:
3684:
3679:
3674:
3669:
3664:
3659:
3654:
3649:
3644:
3639:
3634:
3629:
3624:
3615:
3614:
3609:
3604:
3595:
3593:
3587:
3586:
3584:
3583:
3578:
3573:
3568:
3563:
3558:
3553:
3548:
3543:
3538:
3533:
3528:
3523:
3514:
3513:
3504:
3503:
3498:
3493:
3484:
3483:
3478:
3473:
3468:
3463:
3458:
3453:
3448:
3443:
3438:
3433:
3428:
3423:
3418:
3413:
3408:
3403:
3398:
3393:
3388:
3383:
3381:4'-DMA-7,8-DHF
3378:
3373:
3364:
3362:
3356:
3355:
3353:
3352:
3343:
3342:
3330:
3329:
3324:
3319:
3314:
3309:
3304:
3299:
3294:
3275:
3274:
3268:
3263:
3258:
3253:
3248:
3243:
3238:
3233:
3228:
3223:
3218:
3213:
3208:
3203:
3198:
3189:
3188:
3179:
3178:
3173:
3168:
3163:
3154:
3153:
3148:
3143:
3141:Gambogic amide
3138:
3133:
3128:
3123:
3118:
3113:
3104:
3102:
3093:
3087:
3086:
3084:
3083:
3075:
3073:
3067:
3066:
3064:
3063:
3058:
3053:
3048:
3043:
3038:
3033:
3028:
3023:
3018:
3013:
3004:
3003:
2998:
2989:
2987:
2981:
2980:
2977:
2976:
2974:
2973:
2964:
2962:
2958:
2957:
2955:
2954:
2945:
2944:
2935:
2933:
2927:
2926:
2924:
2923:
2914:
2913:
2911:Artemin (ARTN)
2904:
2902:
2896:
2895:
2893:
2892:
2883:
2882:
2873:
2871:
2865:
2864:
2862:
2861:
2852:
2851:
2846:
2837:
2835:
2826:
2820:
2819:
2817:
2816:
2811:
2806:
2797:
2796:
2791:
2786:
2781:
2776:
2771:
2766:
2761:
2756:
2751:
2746:
2741:
2736:
2731:
2726:
2721:
2712:
2711:
2689:
2680:
2678:
2672:
2671:
2669:
2668:
2659:
2658:
2646:
2645:
2640:
2635:
2630:
2625:
2620:
2615:
2610:
2598:
2597:
2592:
2587:
2582:
2573:
2572:
2567:
2562:
2557:
2552:
2547:
2542:
2537:
2532:
2523:
2521:
2515:
2514:
2511:
2510:
2508:
2507:
2502:
2493:
2492:
2454:
2452:
2448:
2447:
2445:
2444:
2438:
2429:
2428:
2418:
2416:
2410:
2409:
2407:
2406:
2400:
2395:
2390:
2385:
2380:
2375:
2370:
2365:
2356:
2355:
2350:
2345:
2340:
2335:
2326:
2325:
2320:
2315:
2310:
2305:
2300:
2295:
2285:
2283:
2274:
2268:
2267:
2265:
2264:
2259:
2254:
2249:
2244:
2239:
2234:
2225:
2224:
2219:
2214:
2209:
2204:
2199:
2194:
2189:
2184:
2179:
2174:
2169:
2164:
2159:
2154:
2149:
2144:
2139:
2134:
2129:
2120:
2119:
2110:
2109:
2104:
2094:
2092:
2086:
2085:
2082:
2081:
2079:
2078:
2069:
2067:
2063:
2062:
2060:
2059:
2054:
2020:
2011:
2009:
2003:
2002:
2000:
1999:
1989:
1988:
1983:
1978:
1973:
1939:
1930:
1928:
1922:
1921:
1919:
1918:
1909:
1908:
1903:
1894:
1893:
1888:
1883:
1878:
1873:
1868:
1806:
1797:
1795:
1789:
1788:
1786:
1785:
1780:
1775:
1770:
1765:
1723:
1714:
1712:
1703:
1697:
1696:
1693:
1692:
1690:
1689:
1663:
1658:
1653:
1644:
1642:
1636:
1635:
1633:
1632:
1627:
1622:
1613:
1612:
1590:
1588:
1582:
1581:
1579:
1578:
1573:
1568:
1563:
1558:
1549:
1548:
1543:
1538:
1533:
1528:
1523:
1514:
1513:
1503:
1501:
1495:
1494:
1492:
1491:
1486:
1481:
1476:
1471:
1466:
1461:
1456:
1451:
1446:
1437:
1436:
1431:
1426:
1421:
1416:
1411:
1406:
1401:
1396:
1391:
1386:
1381:
1376:
1371:
1362:
1361:
1356:
1351:
1346:
1341:
1336:
1331:
1326:
1321:
1311:
1309:
1296:
1290:
1289:
1287:
1286:
1281:
1276:
1267:
1265:
1259:
1258:
1256:
1255:
1249:
1239:
1238:
1233:
1228:
1219:
1218:
1216:Angiopoietin 3
1213:
1211:Angiopoietin 2
1204:
1203:
1201:Angiopoietin 4
1198:
1196:Angiopoietin 1
1189:
1187:
1181:
1180:
1172:
1170:
1169:
1162:
1155:
1147:
1140:
1139:
1090:
1041:
984:
935:
923:
912:
863:
814:
778:
752:
703:
651:
609:
560:
511:
482:(8): 592–603.
461:
459:
456:
415:
412:
349:
346:
336:
335:
332:
326:
325:
322:
316:
315:
312:
306:
305:
302:
296:
295:
292:
286:
285:
282:
276:
275:
272:
266:
265:
262:
256:
255:
252:
246:
245:
242:
236:
235:
232:
226:
225:
222:
216:
215:
212:
206:
205:
202:
196:
195:
192:
182:
179:
134:VEGF receptors
56:
55:
48:
45:
44:
41:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
4114:
4103:
4100:
4098:
4095:
4094:
4092:
4076:
4073:
4070:
4069:
4066:
4063:
4060:
4056:
4053:
4051:
4048:
4046:
4043:
4041:
4038:
4036:
4033:
4031:
4028:
4026:
4023:
4021:
4018:
4016:
4013:
4010:
4006:
4002:
3999:
3997:
3994:
3992:
3989:
3987:
3984:
3981:
3977:
3974:
3971:
3967:
3963:
3959:
3955:
3951:
3947:
3943:
3939:
3936:
3934:
3931:
3928:
3924:
3921:
3919:
3916:
3913:
3912:
3910:
3906:
3900:
3897:
3894:
3893:
3890:
3887:
3885:
3882:
3880:
3877:
3875:
3872:
3870:
3867:
3864:
3863:
3860:
3857:
3855:
3852:
3850:
3847:
3845:
3842:
3840:
3837:
3835:
3832:
3830:
3827:
3825:
3822:
3820:
3817:
3815:
3812:
3810:
3807:
3805:
3802:
3800:
3797:
3795:
3792:
3790:
3787:
3785:
3782:
3780:
3777:
3775:
3772:
3770:
3767:
3765:
3762:
3760:
3757:
3754:
3753:
3750:
3749:Cyclotraxin B
3747:
3744:
3743:
3739:
3735:
3731:
3727:
3723:
3720:
3718:
3715:
3713:
3710:
3708:
3705:
3702:
3701:
3699:
3697:
3693:
3683:
3680:
3678:
3675:
3673:
3670:
3668:
3665:
3663:
3662:Larotrectinib
3660:
3658:
3655:
3653:
3650:
3648:
3645:
3643:
3640:
3638:
3635:
3633:
3630:
3628:
3625:
3623:
3620:
3617:
3616:
3613:
3610:
3608:
3605:
3603:
3600:
3597:
3596:
3594:
3592:
3588:
3582:
3579:
3577:
3574:
3572:
3569:
3567:
3564:
3562:
3561:Larotrectinib
3559:
3557:
3554:
3552:
3549:
3547:
3544:
3542:
3539:
3537:
3534:
3532:
3529:
3527:
3524:
3522:
3519:
3516:
3515:
3512:
3509:
3506:
3505:
3502:
3499:
3497:
3496:Cyclotraxin B
3494:
3492:
3489:
3486:
3485:
3482:
3479:
3477:
3474:
3472:
3469:
3467:
3464:
3462:
3459:
3457:
3454:
3452:
3449:
3447:
3444:
3442:
3439:
3437:
3434:
3432:
3429:
3427:
3424:
3422:
3419:
3417:
3414:
3412:
3409:
3407:
3406:Amitriptyline
3404:
3402:
3399:
3397:
3394:
3392:
3389:
3387:
3384:
3382:
3379:
3377:
3374:
3372:
3369:
3366:
3365:
3363:
3361:
3357:
3351:
3348:
3345:
3344:
3341:
3338:
3335:
3332:
3331:
3328:
3325:
3323:
3320:
3318:
3315:
3313:
3310:
3308:
3305:
3303:
3300:
3298:
3295:
3293:
3290:
3286:
3283:
3282:Against TrkA:
3280:
3277:
3276:
3272:
3269:
3267:
3264:
3262:
3259:
3257:
3254:
3252:
3249:
3247:
3244:
3242:
3239:
3237:
3236:Larotrectinib
3234:
3232:
3229:
3227:
3224:
3222:
3219:
3217:
3214:
3212:
3209:
3207:
3204:
3202:
3199:
3197:
3194:
3191:
3190:
3187:
3184:
3181:
3180:
3177:
3174:
3172:
3169:
3167:
3166:Dexamethasone
3164:
3162:
3159:
3156:
3155:
3152:
3149:
3147:
3144:
3142:
3139:
3137:
3134:
3132:
3129:
3127:
3124:
3122:
3119:
3117:
3114:
3112:
3111:Amitriptyline
3109:
3106:
3105:
3103:
3101:
3097:
3094:
3092:
3088:
3081:
3077:
3076:
3074:
3072:
3068:
3062:
3059:
3057:
3054:
3052:
3049:
3047:
3044:
3042:
3039:
3037:
3034:
3032:
3029:
3027:
3024:
3022:
3019:
3017:
3014:
3012:
3009:
3006:
3005:
3002:
2999:
2997:
2994:
2991:
2990:
2988:
2986:
2982:
2972:
2969:
2966:
2965:
2963:
2959:
2953:
2950:
2947:
2946:
2943:
2940:
2937:
2936:
2934:
2932:
2928:
2922:
2919:
2916:
2915:
2912:
2909:
2906:
2905:
2903:
2901:
2897:
2891:
2888:
2885:
2884:
2881:
2878:
2875:
2874:
2872:
2870:
2866:
2860:
2857:
2854:
2853:
2850:
2847:
2845:
2842:
2839:
2838:
2836:
2834:
2830:
2827:
2825:
2821:
2815:
2812:
2810:
2807:
2805:
2802:
2799:
2798:
2795:
2792:
2790:
2787:
2785:
2782:
2780:
2777:
2775:
2772:
2770:
2767:
2765:
2762:
2760:
2757:
2755:
2752:
2750:
2747:
2745:
2742:
2740:
2737:
2735:
2732:
2730:
2727:
2725:
2722:
2720:
2717:
2714:
2713:
2709:
2705:
2701:
2697:
2693:
2690:
2688:
2685:
2682:
2681:
2679:
2677:
2673:
2667:
2664:
2661:
2660:
2657:
2654:
2651:
2648:
2647:
2644:
2641:
2639:
2636:
2634:
2631:
2629:
2626:
2624:
2621:
2619:
2616:
2614:
2611:
2609:
2606:
2603:
2600:
2599:
2596:
2593:
2591:
2588:
2586:
2585:Dexamethasone
2583:
2581:
2578:
2575:
2574:
2571:
2568:
2566:
2563:
2561:
2558:
2556:
2553:
2551:
2548:
2546:
2543:
2541:
2538:
2536:
2533:
2531:
2528:
2525:
2524:
2522:
2520:
2516:
2506:
2503:
2501:
2498:
2495:
2494:
2490:
2486:
2482:
2478:
2474:
2470:
2466:
2462:
2459:
2456:
2455:
2453:
2449:
2442:
2439:
2437:
2434:
2431:
2430:
2427:
2423:
2420:
2419:
2417:
2415:
2411:
2404:
2401:
2399:
2396:
2394:
2391:
2389:
2386:
2384:
2381:
2379:
2376:
2374:
2371:
2369:
2366:
2364:
2361:
2358:
2357:
2354:
2351:
2349:
2346:
2344:
2341:
2339:
2336:
2334:
2331:
2328:
2327:
2324:
2321:
2319:
2316:
2314:
2311:
2309:
2306:
2304:
2301:
2299:
2296:
2294:
2293:des(1-3)IGF-1
2290:
2287:
2286:
2284:
2282:
2278:
2275:
2273:
2269:
2263:
2260:
2258:
2257:Telisotuzumab
2255:
2253:
2250:
2248:
2245:
2243:
2240:
2238:
2235:
2233:
2230:
2227:
2226:
2223:
2220:
2218:
2215:
2213:
2210:
2208:
2205:
2203:
2200:
2198:
2195:
2193:
2190:
2188:
2185:
2183:
2180:
2178:
2175:
2173:
2170:
2168:
2165:
2163:
2160:
2158:
2155:
2153:
2150:
2148:
2145:
2143:
2140:
2138:
2135:
2133:
2130:
2128:
2125:
2122:
2121:
2118:
2115:
2114:Potentiators:
2112:
2111:
2108:
2105:
2103:
2099:
2096:
2095:
2093:
2091:
2087:
2077:
2074:
2071:
2070:
2068:
2064:
2058:
2055:
2052:
2048:
2044:
2040:
2036:
2032:
2028:
2024:
2021:
2019:
2016:
2013:
2012:
2010:
2008:
2004:
1997:
1994:
1991:
1990:
1987:
1984:
1982:
1979:
1977:
1976:Selpercatinib
1974:
1971:
1967:
1963:
1959:
1955:
1951:
1947:
1943:
1940:
1938:
1935:
1932:
1931:
1929:
1927:
1923:
1917:
1914:
1911:
1910:
1907:
1904:
1902:
1899:
1896:
1895:
1892:
1889:
1887:
1884:
1882:
1881:Selpercatinib
1879:
1877:
1874:
1872:
1869:
1866:
1862:
1858:
1854:
1850:
1846:
1842:
1838:
1834:
1830:
1826:
1822:
1818:
1814:
1810:
1807:
1805:
1802:
1799:
1798:
1796:
1794:
1790:
1784:
1781:
1779:
1776:
1774:
1773:Selpercatinib
1771:
1769:
1766:
1763:
1759:
1755:
1751:
1747:
1743:
1739:
1735:
1731:
1727:
1724:
1722:
1719:
1716:
1715:
1713:
1711:
1707:
1704:
1702:
1698:
1687:
1683:
1679:
1675:
1671:
1667:
1664:
1662:
1659:
1657:
1654:
1652:
1649:
1646:
1645:
1643:
1641:
1637:
1631:
1628:
1626:
1623:
1621:
1618:
1615:
1614:
1610:
1606:
1602:
1598:
1595:
1592:
1591:
1589:
1587:
1583:
1577:
1574:
1572:
1569:
1567:
1564:
1562:
1559:
1557:
1554:
1551:
1550:
1547:
1544:
1542:
1539:
1537:
1534:
1532:
1529:
1527:
1524:
1522:
1519:
1516:
1515:
1512:
1508:
1505:
1504:
1502:
1500:
1496:
1490:
1487:
1485:
1482:
1480:
1477:
1475:
1472:
1470:
1467:
1465:
1462:
1460:
1457:
1455:
1452:
1450:
1449:Depatuxizumab
1447:
1445:
1442:
1439:
1438:
1435:
1432:
1430:
1427:
1425:
1422:
1420:
1417:
1415:
1412:
1410:
1407:
1405:
1402:
1400:
1397:
1395:
1392:
1390:
1387:
1385:
1382:
1380:
1377:
1375:
1372:
1370:
1367:
1364:
1363:
1360:
1357:
1355:
1352:
1350:
1347:
1345:
1342:
1340:
1337:
1335:
1332:
1330:
1327:
1325:
1322:
1320:
1316:
1313:
1312:
1310:
1308:
1300:
1297:
1295:
1291:
1285:
1282:
1280:
1277:
1275:
1272:
1269:
1268:
1266:
1264:
1260:
1253:
1250:
1247:
1244:
1241:
1240:
1237:
1234:
1232:
1229:
1227:
1224:
1221:
1220:
1217:
1214:
1212:
1209:
1206:
1205:
1202:
1199:
1197:
1194:
1191:
1190:
1188:
1186:
1182:
1178:
1175:
1168:
1163:
1161:
1156:
1154:
1149:
1148:
1145:
1135:
1131:
1126:
1121:
1117:
1113:
1109:
1105:
1101:
1094:
1091:
1086:
1082:
1077:
1072:
1068:
1064:
1060:
1056:
1052:
1045:
1042:
1037:
1033:
1028:
1023:
1019:
1015:
1011:
1007:
1003:
999:
995:
988:
985:
980:
976:
971:
966:
962:
958:
955:(6): 2042–7.
954:
950:
946:
939:
936:
932:
927:
924:
921:
916:
913:
908:
904:
899:
894:
890:
886:
883:(9): 1244–6.
882:
878:
874:
867:
864:
859:
855:
851:
847:
842:
837:
833:
829:
825:
818:
815:
810:
806:
802:
798:
794:
790:
789:Ophthalmology
782:
779:
766:
762:
756:
753:
748:
744:
739:
734:
730:
726:
722:
718:
714:
707:
704:
699:
695:
690:
685:
681:
677:
673:
669:
665:
658:
656:
652:
647:
643:
638:
633:
629:
625:
621:
613:
610:
605:
601:
596:
591:
587:
583:
580:(3): 220–31.
579:
575:
571:
564:
561:
556:
552:
547:
542:
538:
534:
530:
526:
522:
515:
512:
507:
503:
498:
493:
489:
485:
481:
477:
473:
466:
463:
457:
455:
451:
449:
444:
440:
435:
433:
429:
425:
421:
413:
411:
409:
403:
399:
396:
395:Off-label use
392:
388:
384:
382:
378:
372:
370:
364:
362:
358:
354:
347:
345:
343:
333:
331:
328:
327:
323:
321:
318:
317:
313:
311:
308:
307:
303:
301:
298:
297:
293:
291:
288:
287:
283:
281:
278:
277:
273:
271:
268:
267:
263:
261:
258:
257:
253:
251:
248:
247:
243:
241:
238:
237:
233:
231:
228:
227:
223:
221:
218:
217:
213:
211:
208:
207:
203:
201:
198:
197:
193:
190:
189:
180:
178:
176:
172:
168:
163:
161:
156:
152:
148:
146:
142:
137:
135:
131:
127:
123:
119:
115:
111:
107:
103:
99:
93:
66:
62:
52:
42:
40:
36:
31:
19:
4075:Cerebrolysin
4071:
4045:Pleiotrophin
4001:Interleukins
3914:
3895:
3865:
3784:Fruquintinib
3774:Cabozantinib
3755:
3745:
3703:
3667:Lestaurtinib
3618:
3598:
3566:Lestaurtinib
3517:
3507:
3488:Antagonists:
3487:
3421:Deoxygedunin
3376:3,7,8,2'-THF
3367:
3346:
3337:Against NGF:
3336:
3333:
3289:Against NGF:
3288:
3281:
3278:
3241:Lestaurtinib
3192:
3182:
3176:Testosterone
3158:Antagonists:
3157:
3107:
3007:
2992:
2967:
2948:
2938:
2917:
2907:
2886:
2876:
2855:
2840:
2800:
2715:
2683:
2662:
2653:Against NGF:
2652:
2649:
2605:Against NGF:
2604:
2601:
2595:Testosterone
2577:Antagonists:
2576:
2526:
2496:
2457:
2432:
2421:
2398:Teprotumumab
2359:
2329:
2288:
2237:Ficlatuzumab
2232:Emibetuzumab
2228:
2182:JNJ-38877605
2152:Cabozantinib
2123:
2113:
2102:Fosgonimeton
2097:
2072:
2014:
1992:
1933:
1916:Infigratinib
1912:
1897:
1800:
1717:
1651:Betacellulin
1647:
1630:Seribantumab
1616:
1593:
1552:
1517:
1511:Unknown/none
1510:
1506:
1440:
1365:
1324:Betacellulin
1319:Amphiregulin
1314:
1306:(ErbB1/HER1)
1270:
1242:
1222:
1208:Antagonists:
1207:
1192:
1185:Angiopoietin
1107:
1103:
1093:
1058:
1054:
1044:
1001:
997:
987:
952:
948:
938:
926:
915:
880:
876:
866:
831:
827:
817:
792:
788:
781:
769:. Retrieved
764:
755:
720:
716:
706:
671:
667:
627:
623:
612:
577:
573:
563:
531:(3): 232–9.
528:
524:
514:
479:
475:
465:
452:
436:
417:
404:
400:
393:
389:
385:
373:
365:
351:
339:
230:cabozantinib
220:brolucizumab
214:cancer, AMD
164:
157:
153:
149:
138:
64:
60:
59:
4035:Oncomodulin
3899:Aflibercept
3889:Ranibizumab
3884:Ramucirumab
3874:Bevacizumab
3866:Antibodies:
3824:Regorafenib
3764:Altiratinib
3677:ONO-5390556
3647:Entrectinib
3622:Altiratinib
3576:ONO-5390556
3546:Entrectinib
3521:Altiratinib
3307:Frunevetmab
3279:Antibodies:
3256:ONO-5390556
3221:Entrectinib
3196:Altiratinib
3151:Tavilermide
3046:Quizartinib
2985:SCF (c-Kit)
2809:Ramucirumab
2801:Antibodies:
2774:Quizartinib
2724:Avapritinib
2687:Becaplermin
2623:Frunevetmab
2602:Antibodies:
2505:Trofinetide
2436:Dusigitumab
2433:Antibodies:
2388:Robatumumab
2378:Figitumumab
2373:Dalotuzumab
2368:Cixutumumab
2360:Antibodies:
2252:Rilotumumab
2247:Onartuzumab
2242:Flanvotumab
2229:Antibodies:
2197:PF-04217903
2127:Altiratinib
2090:HGF (c-Met)
1993:Antibodies:
1898:Antibodies:
1620:Duligotumab
1617:Antibodies:
1531:Trastuzumab
1521:Ertumaxomab
1518:Antibodies:
1489:Zalutumumab
1484:Panitumumab
1479:Nimotuzumab
1474:Necitumumab
1464:Imgatuzumab
1441:Antibodies:
1424:Osimertinib
1389:Dacomitinib
1284:Dapiclermin
1243:Antibodies:
1226:Altiratinib
574:Cancer Cell
525:Cancer Cell
408:aflibercept
381:verteporfin
357:bevacizumab
353:Ranibizumab
300:regorafenib
290:ranibizumab
280:ramucirumab
210:bevacizumab
110:ranibizumab
106:bevacizumab
4091:Categories
3854:Vandetanib
3819:Rebastinib
3814:Pegaptanib
3804:Nintedanib
3794:Lenvatinib
3759:Agerafenib
3712:Ripretinib
3637:CH-7057288
3536:CH-7057288
3401:7,8,3'-THF
3396:7,8,2'-THF
3322:Ranevetmab
3312:Fulranumab
3266:Rebastinib
3211:CH-7057288
3126:Cenegermin
3011:Agerafenib
2971:Agerafenib
2952:Vandetanib
2921:Vandetanib
2890:Vandetanib
2859:Vandetanib
2804:Olaratumab
2779:Ripretinib
2759:Nintedanib
2744:Lenvatinib
2734:Crenolanib
2719:Agerafenib
2638:Ranevetmab
2628:Fulranumab
2545:Cenegermin
2519:LNGF (p75)
2441:Xentuzumab
2403:Xentuzumab
2348:NVP-AEW541
2343:NVP-ADW742
2338:Linsitinib
2333:BMS-754807
2318:Mecasermin
2217:Tivantinib
2207:PHA-665752
2202:PF-2341066
2172:Golvatinib
2162:Crizotinib
2157:Capmatinib
2147:BMS-777607
2142:Amuvatinib
2018:Ersofermin
1981:Sprifermin
1937:Ersofermin
1886:Sprifermin
1876:Repifermin
1871:Palifermin
1804:Ersofermin
1783:Velafermin
1768:Repifermin
1721:Ersofermin
1640:ErbB4/HER4
1625:Patritumab
1586:ErbB3/HER3
1566:Mubritinib
1526:Pertuzumab
1499:ErbB2/HER2
1429:Vandetanib
1384:Canertinib
1379:Brigatinib
1374:Agerafenib
1354:Nepidermin
1349:Murodermin
1339:Epiregulin
1294:EGF (ErbB)
1252:Nesvacumab
1246:Evinacumab
1236:Rebastinib
1177:modulators
458:References
422:(used for
330:vandetanib
250:lenvatinib
171:pegaptanib
4097:Angiology
3879:Icrucumab
3859:WHI-P 154
3849:Tivozanib
3844:Toceranib
3839:Sunitinib
3834:Sorafenib
3829:Semaxanib
3809:Pazopanib
3799:Motesanib
3789:Lapatinib
3779:Cediranib
3717:Telbermin
3704:Agonists:
3652:GZ-389988
3632:CE-245677
3599:Agonists:
3551:GZ-389988
3531:CE-245677
3431:Diosmetin
3368:Agonists:
3334:Aptamers:
3327:Tanezumab
3302:Fasinumab
3246:Milciclib
3226:GZ-389988
3206:CE-245677
3108:Agonists:
3061:Toceranib
3056:Sunitinib
3051:Sorafenib
3041:Pazopanib
3036:Nilotinib
3031:Masitinib
3021:Dasatinib
2993:Agonists:
2939:Agonists:
2908:Agonists:
2877:Agonists:
2849:Liatermin
2841:Agonists:
2824:RET (GFL)
2814:Tovetumab
2794:Toceranib
2789:Sorafenib
2784:Sunitinib
2769:Radotinib
2764:Pazopanib
2754:Motesanib
2749:Masitinib
2684:Agonists:
2650:Aptamers:
2643:Tanezumab
2618:Fasinumab
2527:Agonists:
2383:Ganitumab
2303:IGF-1 LR3
2222:Volitinib
2177:INCB28060
2167:Foretinib
2073:Agonists:
2057:Trafermin
2015:Agonists:
1996:Burosumab
1986:Trafermin
1934:Agonists:
1901:Aprutumab
1891:Trafermin
1853:10 (KGF2)
1801:Agonists:
1778:Trafermin
1758:10 (KGF2)
1718:Agonists:
1648:Agonists:
1594:Agonists:
1576:Tucatinib
1571:Neratinib
1561:Lapatinib
1469:Matuzumab
1459:Futuximab
1444:Cetuximab
1434:WHI-P 154
1419:Neratinib
1414:Lapatinib
1404:Grandinin
1399:Gefitinib
1394:Erlotinib
1271:Agonists:
1231:CE-245677
1193:Agonists:
1018:1469-493X
320:sunitinib
310:sorafenib
270:ponatinib
260:pazopanib
240:lapatinib
160:cediranib
145:pazopanib
130:pazopanib
122:sorafenib
118:sunitinib
65:anti-VEGF
39:Specialty
33:Anti-VEGF
4061:instead)
4050:Renalase
4011:instead)
3982:instead)
3929:instead)
3769:Axitinib
3738:D (FIGF)
3682:PLX-7486
3672:ONO-4474
3627:AZD-6918
3581:PLX-7486
3571:ONO-4474
3526:AZD-6918
3508:Ligands:
3426:Deprenyl
3386:7,3'-DHF
3317:MEDI-578
3297:ASP-6294
3261:PLX-7486
3251:ONO-4474
3201:AZD-6918
3161:ALE-0540
3082:instead.
3026:Imatinib
3016:Axitinib
2996:Ancestim
2961:Unsorted
2739:Imatinib
2729:Axitinib
2633:MEDI-578
2613:ASP-6294
2580:ALE-0540
2422:Agonists
2363:AVE-1642
2289:Agonists
2212:SU-11274
2098:Agonists
2076:FGF15/19
2066:Unsorted
2031:2 (bFGF)
1950:2 (bFGF)
1817:2 (bFGF)
1734:2 (bFGF)
1556:Afatinib
1507:Agonists
1409:Icotinib
1369:Afatinib
1315:Agonists
1134:26769010
1085:30325017
1036:32027392
979:19342033
907:17431015
858:13505353
850:17021318
809:19118696
771:17 April
747:23028128
698:24788977
646:27025186
604:19249680
555:19249681
506:18650835
414:Research
200:axitinib
158:AZ2171 (
141:axitinib
126:axitinib
43:oncology
3938:Ephrins
3642:DS-6051
3541:DS-6051
3446:LM22A-4
3436:DMAQ-B1
3391:7,8-DHF
3371:3,7-DHF
3340:RBM-004
3285:GBR-900
3216:DS-6051
3186:VM-902A
2656:RBM-004
2353:OSl-906
2313:Insulin
2192:MK-2461
2137:AMG-458
1274:Axokine
1125:8742906
1076:6517135
1027:7003996
970:2847675
898:1954941
738:3475399
689:4292843
595:2874829
546:4540346
497:2874834
334:cancer
324:cancer
314:cancer
304:cancer
284:cancer
274:cancer
264:cancer
254:cancer
244:cancer
234:cancer
204:cancer
165:A 2014
3908:Others
3602:BNN-20
3491:ANA-12
3416:BNN-20
3136:DHEA-S
3121:BNN-27
3116:BNN-20
2555:DHEA-S
2540:BNN-27
2535:BNN-20
2451:Others
1656:Epigen
1334:Epigen
1132:
1122:
1083:
1073:
1034:
1024:
1016:
977:
967:
905:
895:
856:
848:
807:
745:
735:
696:
686:
644:
624:Lancet
602:
592:
553:
543:
504:
494:
181:Cancer
128:, and
4057:(see
4007:(see
3978:(see
3925:(see
3657:K252a
3556:K252a
3231:K252a
3171:FX007
2931:GFRα4
2900:GFRα3
2869:GFRα2
2833:GFRα1
2461:IGFBP
2414:IGF-2
2393:R1507
2281:IGF-1
2187:K252a
2007:FGFR4
1926:FGFR3
1793:FGFR2
1710:FGFR1
854:S2CID
379:with
191:Drug
49:[
4059:here
4009:here
3980:here
3927:here
3722:VEGF
3696:VEGF
3612:NT-3
3607:DHEA
3591:TrkC
3511:DHEA
3481:TDP6
3461:NT-4
3456:NT-3
3441:HIOC
3411:BDNF
3360:TrkB
3131:DHEA
3100:TrkA
3080:here
3078:See
3071:TGFβ
2676:PDGF
2570:NT-4
2565:NT-3
2550:DHEA
2530:BDNF
1279:CNTF
1263:CNTF
1130:PMID
1108:2016
1081:PMID
1059:2018
1032:PMID
1014:ISSN
1002:2020
975:PMID
903:PMID
846:PMID
805:PMID
773:2013
743:PMID
694:PMID
672:2014
642:PMID
600:PMID
551:PMID
502:PMID
294:AMD
224:AMD
194:Use
143:and
3476:R13
3146:NGF
3091:Trk
2560:NGF
2272:IGF
2132:AM7
2023:FGF
1942:FGF
1843:),
1841:KGF
1809:FGF
1726:FGF
1701:FGF
1303:EGF
1120:PMC
1112:doi
1071:PMC
1063:doi
1022:PMC
1006:doi
965:PMC
957:doi
893:PMC
885:doi
836:doi
832:355
797:doi
793:116
733:PMC
725:doi
684:PMC
676:doi
632:doi
628:387
590:PMC
582:doi
541:PMC
533:doi
492:PMC
484:doi
4093::
3970:B3
3968:,
3966:B2
3964:,
3962:B1
3960:,
3958:A5
3956:,
3954:A4
3952:,
3950:A3
3948:,
3946:A2
3944:,
3942:A1
3736:,
3732:,
3728:,
3471:R7
3287:;
2706:,
2702:,
2698:,
2487:,
2483:,
2479:,
2475:,
2471:,
2467:,
2424::
2291::
2100::
2051:19
2049:,
2045:,
2041:,
2037:,
2033:,
2029:,
1970:23
1968:,
1966:18
1964:,
1960:,
1956:,
1952:,
1948:,
1865:22
1863:,
1861:18
1859:,
1857:17
1855:,
1851:,
1847:,
1835:,
1831:,
1827:,
1823:,
1819:,
1815:,
1762:20
1760:,
1756:,
1752:,
1748:,
1744:,
1740:,
1736:,
1732:,
1684:,
1680:,
1676:,
1672:,
1607:,
1603:,
1509::
1317::
1128:.
1118:.
1106:.
1102:.
1079:.
1069:.
1057:.
1053:.
1030:.
1020:.
1012:.
1000:.
996:.
973:.
963:.
953:93
951:.
947:.
901:.
891:.
881:91
879:.
875:.
852:.
844:.
830:.
826:.
803:.
791:.
763:.
741:.
731:.
719:.
715:.
692:.
682:.
670:.
666:.
654:^
640:.
626:.
622:.
598:.
588:.
578:15
576:.
572:.
549:.
539:.
529:15
527:.
523:.
500:.
490:.
478:.
474:.
437:A
434:.
124:,
120:,
80:dʒ
4003:/
3972:)
3940:(
3740:)
3734:C
3730:B
3726:A
3724:(
3273:)
2710:)
2708:D
2704:C
2700:B
2696:A
2694:(
2491:)
2489:7
2485:6
2481:5
2477:4
2473:3
2469:2
2465:1
2463:(
2053:)
2047:9
2043:8
2039:6
2035:4
2027:1
2025:(
1972:)
1962:9
1958:8
1954:4
1946:1
1944:(
1867:)
1849:9
1845:8
1839:(
1837:7
1833:6
1829:5
1825:4
1821:3
1813:1
1811:(
1764:)
1754:8
1750:6
1746:5
1742:4
1738:3
1730:1
1728:(
1688:)
1682:4
1678:3
1674:2
1670:1
1668:(
1611:)
1605:2
1601:1
1599:(
1166:e
1159:t
1152:v
1136:.
1114::
1087:.
1065::
1038:.
1008::
981:.
959::
909:.
887::
860:.
838::
811:.
799::
775:.
749:.
727::
721:2
700:.
678::
648:.
634::
606:.
584::
557:.
535::
508:.
486::
480:8
92:/
89:f
86:ɛ
83:ˈ
77:ɛ
74:v
71:/
67:(
53:]
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.